Previous 10 | Next 10 |
Summary AstraZeneca’s stock dipped 5.8% in August, the biggest monthly fall in 2022, raising the question whether it is a good time to buy the otherwise high-performing stock on dip. Factors like relatively better performance by healthcare stocks in the current sluggish eco...
Summary Viatris's total revenue was $4,116.8 million in Q2 2022, down 10.1% year-on-year. Sales of the company's branded medicines have been declining since the formation of Viatris in 2020. The company has a dividend yield of 5.08%, but dividend payouts are at risk from 2026....
Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy alone AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with local...
AstraZeneca's ( NASDAQ: AZN ) Forxiga was approved in China to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chr...
The U.S. Food and Drug Administration (FDA) approved AstraZeneca's ( NASDAQ: AZN ) Imfinzi (durvalumab), in combination with chemotherapy (gemcitabine plus cisplatin) to treat adult patients with locally advanced or metastatic biliary tract cancer (BTC). The approval w...
Summary Today, we take a look at BridgeBio Pharma, whose stock had a large fall at the end of 2021 on some disappointing trial results. However, the company has several other late-stage candidates in development as well as collaboration deals with drug giants like Bristol Myers Sq...
Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point Since the company began developing its patented DehydraTECH(TM) technology in 20...
A committee of Japan's Ministry of Health, Labour and Welfare approved AstraZeneca's COVID therapy ( NASDAQ: AZN ) Evusheld. The panel also approved the expanded use of Pfizer ( NYSE: PFE ) and BioNTech's ( NASDAQ: BNTX ) COVID-19 vac...
Summary EFV represents a traditional profile of value stocks. It offers high earnings yield and dividend yields, with substantial US financial exposures. The heavy financial exposures work out for the current environment, EFV looks like a decent ETF. The iShares MSCI EAF...
The Japanese Ministry of Health, Labour and Welfare approved AstraZeneca's ( NASDAQ: AZN ) Ultomiris to treat adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control wi...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
Thursday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the SUPERNOVA Phase 3 COVID-19 pre-exposure prophylaxis...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
2024-05-12 08:20:00 ET Many healthcare investors look at Johnson & Johnson (NYSE: JNJ) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk. The company continually runs into legal problems, and I can't help but wonder if one day i...